Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.

PURPOSE To determine if repeated intravenous exposures to gadolinium-based contrast agents (GBCAs) are associated with neuronal tissue deposition. MATERIALS AND METHODS In this institutional review board-approved single-center study, signal intensities from T1-weighted magnetic resonance (MR) images and postmortem neuronal tissue samples from 13 patients who underwent at least four GBCA-enhanced brain MR examinations between 2000 and 2014 (contrast group) were compared with those from 10 patients who did not receive GBCA (control group). Antemortem consent was obtained from all study participants. Neuronal tissues from the dentate nuclei, pons, globus pallidus, and thalamus of these 23 deceased patients were harvested and analyzed with inductively coupled plasma mass spectrometry (ICP-MS), transmission electron microscopy, and light microscopy to quantify, localize, and assess the effects of gadolinium deposition. Associations between cumulative gadolinium dose, changes in T1-weighted MR signal intensity, and ICP-MS-derived tissue gadolinium concentrations were examined by using the Spearman rank correlation coefficient (ρ). RESULTS Compared with neuronal tissues of control patients, all of which demonstrated undetectable levels of gadolinium, neuronal tissues of patients from the contrast group contained 0.1-58.8 μg gadolinium per gram of tissue, in a significant dose-dependent relationship that correlated with signal intensity changes on precontrast T1-weighted MR images (ρ = 0.49-0.93). All patients in the contrast group had relatively normal renal function at the time of MR examination. Gadolinium deposition in the capillary endothelium and neural interstitium was observed only in the contrast group. CONCLUSION Intravenous GBCA exposure is associated with neuronal tissue deposition in the setting of relatively normal renal function. Additional studies are needed to investigate the clinical significance of these findings and the generalizability to other GBCAs. Online supplemental material is available for this article.

[1]  R R Edelman,et al.  Magnetic resonance imaging (1). , 1993, The New England journal of medicine.

[2]  S. Quay,et al.  A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.

[3]  R. Brasch,et al.  Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. , 1984, AJR. American journal of roentgenology.

[4]  Bradley J. Erickson,et al.  Functional requirements of a desktop clinical image display application , 2001, Journal of Digital Imaging.

[5]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[6]  V. Runge,et al.  MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.

[7]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[8]  P. Hauschka,et al.  Incorporation of excess gadolinium into human bone from medical contrast agents. , 2009, Metallomics : integrated biometal science.

[9]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[10]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[11]  P. Jungers,et al.  Osmotic Nephrosis Induced by Water-Soluble Triiodinated Contrast Media in Man. A Retrospective Study of 47 Cases. , 1975, Radiology.

[12]  N. Fukumitsu,et al.  Imaging of Bilateral Striopallidodentate Calcinosis , 2002, Clinical nuclear medicine.

[13]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[14]  P. Hals,et al.  Biodistribution and toxicity of MR imaging contrast media , 1993, Journal of magnetic resonance imaging : JMRI.

[15]  A. Aisen,et al.  Preliminary clinical trial of gadodiamide injection: A new nonionic gadolinium contrast agent for MR imaging , 1991, Journal of magnetic resonance imaging : JMRI.

[16]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[17]  Luca Roccatagliata,et al.  Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. , 2009, Radiology.

[18]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[19]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  Vincenzo Di Lazzaro,et al.  Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.

[21]  U. Karst,et al.  Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. , 2013, Analytica chimica acta.

[22]  H. Ellinger-Ziegelbauer,et al.  The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats , 2011, Investigative radiology.

[23]  D. Worah,et al.  Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. , 1993, Investigative radiology.

[24]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[25]  R. Edelman,et al.  Magnetic resonance imaging (2) , 1993, The New England journal of medicine.

[26]  J. Gauvrit,et al.  Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents: The Prospective Fibrose Nephrogénique Systémique Study , 2014, Investigative radiology.

[27]  Shigeru Furui,et al.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.

[28]  Zhuxian Zhou,et al.  Gadolinium-based contrast agents for magnetic resonance cancer imaging. , 2013, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[29]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.